Stock Track | Supernus Pharmaceuticals Plunges 12.28% After-Hours Despite Beating Q3 Estimates

Stock Track11-05

Supernus Pharmaceuticals (NASDAQ: SUPN) saw its stock price plummet 12.28% in after-hours trading on Tuesday, despite reporting third-quarter earnings that beat analyst expectations. The biopharmaceutical company's financial results reveal a complex picture of growth mixed with significant losses.

For the third quarter of 2025, Supernus reported a loss of $0.80 per share, which, while better than the analyst consensus estimate of a $1.10 loss, represents a stark reversal from the $0.69 earnings per share reported in the same period last year. This 215.94% decrease in earnings appears to have spooked investors, overshadowing the company's revenue performance. Quarterly sales came in at $192.103 million, beating the analyst estimate of $180.523 million and showing a 9.34% increase from the previous year.

Despite the sales growth, Supernus faces challenges, as evidenced by its operating earnings of negative $60.231 million for the quarter. The company's outlook for the full fiscal year projects revenue between $685-705 million and adjusted operating earnings of $125-145 million. While these figures suggest ongoing growth, the significant quarterly loss and the dramatic shift from profit to loss compared to the previous year seem to have shaken investor confidence, leading to the sharp after-hours decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155637272?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 05:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155637272","market":"hk","top_or_hot":-1,"title":"Stock Track | Supernus Pharmaceuticals Plunges 12.28% After-Hours Despite Beating Q3 Estimates","media":"Stock Track","content":"<p>Supernus Pharmaceuticals (NASDAQ: SUPN) saw its stock price plummet 12.28% in after-hours trading on Tuesday, despite reporting third-quarter earnings that beat analyst expectations. The biopharmaceutical company's financial results reveal a complex picture of growth mixed with significant losses.</p>\n\n<p>For the third quarter of 2025, Supernus reported a loss of $0.80 per share, which, while better than the analyst consensus estimate of a $1.10 loss, represents a stark reversal from the $0.69 earnings per share reported in the same period last year. This 215.94% decrease in earnings appears to have spooked investors, overshadowing the company's revenue performance. Quarterly sales came in at $192.103 million, beating the analyst estimate of $180.523 million and showing a 9.34% increase from the previous year.</p>\n\n<p>Despite the sales growth, Supernus faces challenges, as evidenced by its operating earnings of negative $60.231 million for the quarter. The company's outlook for the full fiscal year projects revenue between $685-705 million and adjusted operating earnings of $125-145 million. While these figures suggest ongoing growth, the significant quarterly loss and the dramatic shift from profit to loss compared to the previous year seem to have shaken investor confidence, leading to the sharp after-hours decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Supernus Pharmaceuticals Plunges 12.28% After-Hours Despite Beating Q3 Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Supernus Pharmaceuticals Plunges 12.28% After-Hours Despite Beating Q3 Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 05:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Supernus Pharmaceuticals (NASDAQ: SUPN) saw its stock price plummet 12.28% in after-hours trading on Tuesday, despite reporting third-quarter earnings that beat analyst expectations. The biopharmaceutical company's financial results reveal a complex picture of growth mixed with significant losses.</p>\n\n<p>For the third quarter of 2025, Supernus reported a loss of $0.80 per share, which, while better than the analyst consensus estimate of a $1.10 loss, represents a stark reversal from the $0.69 earnings per share reported in the same period last year. This 215.94% decrease in earnings appears to have spooked investors, overshadowing the company's revenue performance. Quarterly sales came in at $192.103 million, beating the analyst estimate of $180.523 million and showing a 9.34% increase from the previous year.</p>\n\n<p>Despite the sales growth, Supernus faces challenges, as evidenced by its operating earnings of negative $60.231 million for the quarter. The company's outlook for the full fiscal year projects revenue between $685-705 million and adjusted operating earnings of $125-145 million. While these figures suggest ongoing growth, the significant quarterly loss and the dramatic shift from profit to loss compared to the previous year seem to have shaken investor confidence, leading to the sharp after-hours decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SUPN","symbol_name":"Supernus Pharmaceuticals","start_time":0,"source_url":"","article_id":"1155637272","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155637272","pubTimestamp":1762292401,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Supernus Pharmaceuticals (NASDAQ: SUPN) saw its stock price plummet 12.28% in after-hours trading on Tuesday, despite reporting third-quarter earnings that beat analyst expectations. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SUPN":"Supernus Pharmaceuticals"},"translate_title":"个股追踪|尽管Q3超预期，Supernus Pharmaceuticals盘后暴跌12.28%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SUPN":1},"content_text":"Supernus Pharmaceuticals (NASDAQ: SUPN) saw its stock price plummet 12.28% in after-hours trading on Tuesday, despite reporting third-quarter earnings that beat analyst expectations. The biopharmaceutical company's financial results reveal a complex picture of growth mixed with significant losses.\nFor the third quarter of 2025, Supernus reported a loss of $0.80 per share, which, while better than the analyst consensus estimate of a $1.10 loss, represents a stark reversal from the $0.69 earnings per share reported in the same period last year. This 215.94% decrease in earnings appears to have spooked investors, overshadowing the company's revenue performance. Quarterly sales came in at $192.103 million, beating the analyst estimate of $180.523 million and showing a 9.34% increase from the previous year.\nDespite the sales growth, Supernus faces challenges, as evidenced by its operating earnings of negative $60.231 million for the quarter. The company's outlook for the full fiscal year projects revenue between $685-705 million and adjusted operating earnings of $125-145 million. While these figures suggest ongoing growth, the significant quarterly loss and the dramatic shift from profit to loss compared to the previous year seem to have shaken investor confidence, leading to the sharp after-hours decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155637272","isCrawlerRequest":true}